In the days of the Armada, a fleet of warships, the scuttlebutt was the rumor or gossip that would spread throughout the ship. Today, Armada Law Corp presents The Scuttlebutt, a daily summery of news articles that people within the cannabis, hemp and plant medicine industries are chatting about along with links to the full articles.
In today’s news:
REVOLUTION, EVOLUTION, AND DEVALUATION: 27 YEARS OF MEDICAL MARIJUANA AND 7 YEARS OF COMMERCIAL CANNABIS IN CALIFORNIA
#californiacannabis – “This November 5th marked the 27th anniversary of California’s Compassionate Use Act, Proposition 215, the first law in the nation to permit medicinal marijuana use. November 9th also marked seven years since voters approved Proposition 64, which legalized commercial cannabis and adult use in the state….”
Hawaii Attorney General Unveils Draft Marijuana Legalization Bill, Drawing Mixed Reactions From Lawmakers And Advocates
#cannabisindustry – “Hawaii’s attorney general has released a comprehensive proposal to legalize adult-use marijuana—with lawmakers already expressing interest in advancing it as advocates call for revisions to bolster equity provisions and remove language that could perpetuate criminalization.
Attorney General Anne Lopez (D), who announced her office’s support for cannabis legalization in April and pledged to work with the legislature to enact the reform, unveiled the 294-page legislation on Friday. Under the proposal, a regulatory framework would be established to allow adults 21 and older to possess, cultivate and purchase marijuana from licensed retailers.
Hawaii lawmakers have introduced legalization legislation in recent sessions, with the Senate passing a reform bill in March, but it’s yet to be enacted. Legislators and the attorney general have signaled that 2024 is the year legalization will become law….”
Missouri Revokes License of Cannabis Company That Had 63k Products Recalled
#cannabisregulations – “Missouri cannabis regulators have revoked the manufacturing facility license of Delta Extractions – the company that, in August, was the subject of a near-63,000 product recall. In a press release, the state Division of Cannabis Regulation (DCR) said the revocation is meant to “ensure the health and safety of Missourians and the integrity of Missouri’s voter-approved regulatory program for cannabis.”
Delta Extraction’s license was already suspended by the DCR after the company admitted to sourcing THC-A from outside the Missouri cannabis program, converting the THC-A to THC, and selling that THC within Missouri’s regulated market, which violates state law. In a statement, Amy Moore, director of the DCR said that while Delta’s use of out-of-state cannabis “has been well-publicized and is a critical issue” the agency “found numerous other violations of rules,” including failure to track products in the state’s seed-to-sale system, falsification of products put into the seed-to-sale tracking system, and vast failures with regard to facility security….”
Read More: https://www.ganjapreneur.com/missouri-revokes-license-of-cannabis-company-that-had-63k-products-recalled/
Big Brother Cancels Trip, Court Says Not So Fast My Friend
#psychedelics – “A few weeks ago, the Ninth Circuit Court of Appeals in Aggarwal v. U.S. DEA directed the U.S. Drug Enforcement Agency (DEA) to reconsider its decision not to transfer psilocybin from Schedule I to Schedule II.
Since at least 2021, Dr. Sunil Aggarwal has been working to legally obtain psilocybin for terminally ill cancer patients undergoing end-of-life care. Because psilocybin is a Schedule I drug under the Controlled Substance Act (CSA), obtaining the drug to treat his patients was “practically and legally difficult” according to his lawyers. Aggarwal turned to the DEA, petitioning the agency to transfer psilocybin from Schedule I to Schedule II. The DEA denied the petition in a four-sentence letter. Aggarwal then looked to the Ninth Circuit.
The Ninth Circuit sided with Aggarwal, at least for now and at least in part. The court held that the “DEA failed to provide sufficient analysis to allow its path to be reasonably discerned” and “failed to clearly indicate that it ha[d] considered the potential problem identified in the petition.” More specifically, the Ninth Circuit noted that the DEA failed to define “currently accepted medical use with severe restrictions,” which was the applicable standard for rescheduling on which Aggarwal relied. The court directed the DEA to clarify or reevaluate its position…..”